药物与舌下免疫治疗片剂治疗过敏性鼻炎的Meta分析
该Meta分析纳入随机双盲安慰剂对照试验,评估药物和舌下免疫治疗片剂对季节性及常年性过敏性鼻炎鼻部症状的疗效。主要结局为总鼻症状评分(TNSS)与安慰剂的平均数值差异。结果显示所有治疗均显著改善鼻部症状,但试验异质性和发表偏倚限制了不同治疗类别间的比较。
要点
- 在成人/青少年季节性过敏性鼻炎中,鼻内糖皮质激素的TNSS改善幅度最大(1.38)。
- 舌下免疫治疗片剂在允许使用补救药物的情况下仍显著改善TNSS。
- 广泛异质性和发表偏倚提示应谨慎解读不同治疗类别间的比较。
核心结论
- 所有药物和舌下免疫治疗片剂均显著改善季节性及常年性过敏性鼻炎的鼻部症状。
- 舌下免疫治疗片剂在允许使用补救药物的情况下仍能改善TNSS。
- 广泛的试验异质性和发表偏倚阻碍了不同治疗类别间疗效的比较。
研究设计与样本
- 系统检索PubMed/EMBASE至2019年7月18日的随机双盲安慰剂对照试验(PROSPERO CRD42018105632)。
- 采用随机效应Meta分析,以总鼻症状评分(TNSS,0-12)与安慰剂的平均数值差异为主要结局。
- 评估发表偏倚并进行敏感性分析。
- 纳入的儿童季节性/常年性过敏性鼻炎试验数量有限,限制了Meta分析。
主要发现
- 成人/青少年季节性过敏性鼻炎:鼻内糖皮质激素TNSS差异1.38(95%CI 1.18, 1.58;39项试验)。
- 成人/青少年季节性过敏性鼻炎:鼻内抗组胺药/鼻内糖皮质激素复方TNSS差异1.34(95%CI 1.15, 1.54;4项试验)。
- 成人/青少年季节性过敏性鼻炎:鼻内抗组胺药TNSS差异0.72(95%CI 0.56, 0.89;13项试验)。
- 成人/青少年季节性过敏性鼻炎:口服抗组胺药TNSS差异0.62(95%CI 0.35, 0.90;18项试验)。
- 成人/青少年季节性过敏性鼻炎:舌下免疫治疗片剂TNSS差异0.57(95%CI 0.41, 0.73;4项试验);孟鲁司特TNSS差异0.48(95%CI 0.36, 0.60;10项试验)。
临床怎么用
- 临床可参考各治疗类别对TNSS的改善幅度选择药物或舌下免疫治疗片剂。
- 需注意舌下免疫治疗片剂试验中允许使用补救药物,而多数药物试验禁止使用。
- 因异质性和发表偏倚,不宜直接比较不同治疗类别的疗效大小。
局限性
- 广泛的试验异质性和强烈的发表偏倚迹象。
- 儿童季节性/常年性过敏性鼻炎的可纳入试验数量有限。
- 药物试验与舌下免疫治疗片剂试验在补救药物允许使用方面存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for seasonal and perennial allergic rhinitis (SAR/PAR) include pharmacotherapies and allergy immunotherapy. These meta-analyses evaluated the efficacy of pharmacotherapies and sublingual immunotherapy tablets (SLIT-tablets) versus placebo on nasal symptoms associated with SAR and PAR. METHODS: Randomized, double-blind, placebo-controlled trials were identified from systematic PubMED/EMBASE searches through 7/18/2019 (PROSPERO protocol CRD42018105632). The primary outcome was mean numerical difference in total nasal symptom score (TNSS; 0-12) between active treatment and placebo at the end of the assessment period. Random-effects meta-analyses estimated the mean difference for each medication group weighted by the inverse of the trial variance. Publication bias assessments and sensitivity analyses were conducted. RESULTS: Rescue symptom-relieving pharmacotherapy was prohibited in most pharmacotherapy trials but was allowed in all SLIT-tablet trials. For adult/adolescent SAR, the mean numerical difference (95% CI) in TNSS versus placebo was: intranasal corticosteroids (INCS)=1.38 (1.18, 1.58; 39 trials); combination intranasal antihistamine/INCS=1.34 (1.15, 1.54; 4 trials); intranasal antihistamines=0.72 (0.56, 0.89; 13 trials); oral antihistamine=0.62 (0.35, 0.90; 18 trials); SLIT-tablets=0.57 (0.41, 0.73; 4 trials); and montelukast=0.48 (0.36, 0.60; 10 trials). For adult/adolescent PAR, mean difference in TNSS versus placebo (95% CI) was: INCS=0.82 (0.66, 0.97; 14 trials); SLIT-tablets=0.65 (0.42, 0.88; 3 trials); and oral antihistamine=0.27 (0.11, 0.42; 3 trials). The number of eligible trials limited meta-analyses for pediatric SAR/PAR. CONCLUSIONS: All treatments significantly improved nasal symptoms versus placebo. SLIT-tablets provided improvement in TNSS despite access to rescue symptom-relieving pharmacotherapy. Extensive trial heterogeneity and strong indications of publication bias preclude the comparison of treatment effects among treatment classes.
引用
- Meltzer EO, Wallace D, Friedman HS, et al. Meta-analyses of the efficacy of pharmacotherapies and sublingual allergy immunotherapy tablets for allergic rhinitis in adults and children. Rhinology. 2021. PMID: 34463311. doi:10.4193/Rhin21.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。